SUCCESSFUL ENGRAFTMENT OF T-CELL-DEPLETED HAPLOIDENTICAL 3-LOCI INCOMPATIBLE TRANSPLANTS IN LEUKEMIA PATIENTS BY ADDITION OF RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR-MOBILIZED PERIPHERAL-BLOOD PROGENITOR CELLS TO BONE-MARROW INOCULUM

被引:486
作者
AVERSA, F
TABILIO, A
TERENZI, A
VELARDI, A
FALZETTI, F
GIANNONI, C
IACUCCI, R
ZEI, T
MARTELLI, MP
GAMBELUNGHE, C
ROSSETTI, M
CAPUTO, P
LATINI, P
ARISTEI, C
RAYMONDI, C
REISNER, Y
MARTELLI, MF
机构
[1] BLOOD BANK,PERUGIA,ITALY
[2] POLICLIN MONTELUCE,DEPT MED PHYS,PERUGIA,ITALY
[3] WEIZMANN INST SCI,DEPT BIOPHYS,REHOVOT,ISRAEL
关键词
D O I
10.1182/blood.V84.11.3948.bloodjournal84113948
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients who undergo transplantation with haploidentical ''three-loci'' mismatched T-cell-depleted bone marrow (BM) are at high risk for graft failure. To overcome the host-versus-graft barrier, we increased the size of the graft inoculum, which has been shown to be a major factor in controlling both immune rejection and stem cell competition in murine models. Seventeen patients (mean age, 23.2 years; range, 6 to 51 years) with end-stage chemoresistant leukemia were received transplants of a combination of BM with recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells from HLA-haploidentical ''three-loci'' incompatible family members. The average concentration of colony-forming unit-granulocyte-macrophage in the final inoculum was sevenfold to 10-fold greater than that found in BM alone. The sole graft-versus-host disease (GVHD) prophylaxis consisted of T-cell depletion of the graft by the soybean agglutination and E-rosetting technique. The conditioning regimen included total body irradiation in a single fraction at a fast dose rate, antithymocyte globulin, cyclophosphamide and thiotepa to provide both immunosuppression and myeloablation. One patient rejected the graft and the other 16 had early and sustained full donor-type engraftment. One patient who received a much greater quantity of T lymphocytes than any other patient died from grade IV acute GVHD. There were no other cases of GVHD greater than or equal to grade II. Nine patients died from transplant-related toxicity, 2 relapsed, and 6 patients are alive and event-free at a median follow-up of 230 days (range, 100 to 485 days). Our results show that a highly immunosuppressive and myeloablative conditioning followed by transplantation of a large number of stem cells depleted of T lymphocytes by soybean agglutination and E-rosetting technique has made transplantation of three HLA-antigen disparate grafts possible, with only rare cases of GVHD. (C) 1994 by The American Society of Hematology.
引用
收藏
页码:3948 / 3955
页数:8
相关论文
共 56 条
  • [1] EFFECT OF HLA COMPATIBILITY ON ENGRAFTMENT OF BONE-MARROW TRANSPLANTS IN PATIENTS WITH LEUKEMIA OR LYMPHOMA
    ANASETTI, C
    AMOS, D
    BEATTY, PG
    APPELBAUM, FR
    BENSINGER, W
    BUCKNER, CD
    CLIFT, R
    DONEY, K
    MARTIN, PJ
    MICKELSON, E
    NISPEROS, B
    OQUIGLEY, J
    RAMBERG, R
    SANDERS, JE
    STEWART, P
    STORB, R
    SULLIVAN, KM
    WITHERSPOON, RP
    THOMAS, ED
    HANSEN, JA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (04) : 197 - 204
  • [2] ANASETTI C, 1994, J CELL BIOCH B, V18, P48
  • [3] ARNOLD R, 1993, BONE MARROW TRANSPL, V12, pS11
  • [4] ARTHUR C, 1987, Bone Marrow Transplantation, V2, P137
  • [5] AVERSA F, 1993, BLOOD, V82, pA313
  • [6] BACIGALUPO A, 1994, BONE MARROW TRANSPL, V13, P783
  • [7] HEMATOPOIETIC-CELLS MOBILIZED INTO THE CIRCULATION BY LENOGRASTIM AS ALTERNATIVE TO BONE-MARROW FOR ALLOGENEIC TRANSPLANTS
    BAUMANN, I
    TESTA, NG
    LANGE, C
    DEWYNTER, E
    LUFT, T
    DEXTER, TM
    VANHOEF, MEHM
    HOWELL, A
    [J]. LANCET, 1993, 341 (8841) : 369 - 369
  • [8] MARROW TRANSPLANTATION FROM RELATED DONORS OTHER THAN HLA-IDENTICAL SIBLINGS
    BEATTY, PG
    CLIFT, RA
    MICKELSON, EM
    NISPEROS, BB
    FLOURNOY, N
    MARTIN, PJ
    SANDERS, JE
    STEWART, P
    BUCKNER, CD
    STORB, R
    THOMAS, ED
    HANSEN, JA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (13) : 765 - 771
  • [9] BEATTY PG, 1994, J CELL BIOCH B, V18, P49
  • [10] BENSINGER W, 1993, BLOOD, V81, P3158